Press-release for stocks related to program for sny

tags : Program symbols : Sny

save search

MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)
Published: 2024-02-26 (Crawled : 13:00) - globenewswire.com
MLTX | $41.14 -2.49% -2.55% 280K

| -21.19% | O: 0.0% H: 2.86% C: 0.13%
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -4.68% | O: -0.82% H: 0.0% C: 0.0%
SNY | News | $47.125 1.78% 1.75% 2.1M

Health Technology

| -4.35% | O: 0.89% H: 0.0% C: 0.0%
nanobody fda positive ema program

Press Release: Peer support, flexible work arrangements, salary for a year: Sanofi launches global program for employees affected by cancer and critical illnesses
Published: 2024-02-05 (Crawled : 07:00) - globenewswire.com
SNY | News | $47.125 1.78% 1.75% 2.1M

Health Technology

| -3.61% | O: -1.85% H: 0.0% C: 0.0%
work cancer global program sanofi

Innate Pharma Announces U.S. FDA Lifts Partial Clinical Hold on Lacutamab Clinical Program
Published: 2024-01-04 (Crawled : 08:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -7.51% | O: 1.62% H: 0.0% C: 0.0%
SNY | News | $47.125 1.78% 1.75% 2.1M

Health Technology

| -7.56% | O: 1.12% H: 0.93% C: 0.77%
IPHA | $2.28 -6.56% -7.02% 9.5K

Health Technology

| -12.95% | O: 6.47% H: 3.65% C: -2.36%
fda pharma program

First Wave BioPharma Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program
Published: 2023-12-27 (Crawled : 11:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -6.51% | O: 0.36% H: 0.03% C: 0.03%
FWBI | $2.94 13.08% 11.26% 83K

Manufacturing

| -21.14% | O: 251.76% H: 11.79% C: -57.4%
SNY | News | $47.125 1.78% 1.75% 2.1M

Health Technology

| -5.0% | O: 1.2% H: 0.0% C: 0.0%
first pipeline biopharma niclosamide program

Press Release: Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint
Published: 2023-12-21 (Crawled : 07:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -3.34% | O: -0.1% H: 0.0% C: 0.0%
SNY | News | $47.125 1.78% 1.75% 2.1M

Health Technology

| -5.12% | O: -0.08% H: 0.0% C: 0.0%
program trial sanofi

FDA Puts Clinical Hold on Roche BTK Inhibitor Multiple Sclerosis Program
Published: 2023-12-05 (Crawled : 13:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -1.28% | O: 0.27% H: 0.12% C: 0.12%
SNY | News | $47.125 1.78% 1.75% 2.1M

Health Technology

| -1.09% | O: -0.5% H: 0.0% C: 0.0%
fda sclerosis program roche

Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis
Published: 2023-11-14 (Crawled : 14:30) - globenewswire.com
XBIT | $8.045 0.06% 0.06% 58K

Health Technology

| 102.29% | O: 1.02% H: 2.27% C: -4.03%
SNY | News | $47.125 1.78% 1.75% 2.1M

Health Technology

| 1.97% | O: 0.68% H: 0.0% C: 0.0%
program

Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19
Published: 2023-10-26 (Crawled : 11:00) - globenewswire.com
PFE | News A | $26.26 1.0% -0.08% 36M

Health Technology

| -14.55% | O: -0.39% H: 2.48% C: 1.8%
SNY | News | $47.125 1.78% 1.75% 2.1M

Health Technology

| -12.84% | O: 0.09% H: 0.0% C: 0.0%
BNTX | News | $88.01 1.38% 1.36% 390K

Health Technology

| -7.6% | O: 0.99% H: 1.81% C: 0.47%
covid-19 vaccine positive influenza topline program

Recludix Pharma Presents Preclinical Data from its STAT3 Inhibitor Program at the International Conference of the Inflammation Research Association (IRA)
Published: 2023-10-17 (Crawled : 23:00) - biospace.com/
SNY | News | $47.125 1.78% 1.75% 2.1M

Health Technology

| -15.29% | O: -0.4% H: 0.0% C: 0.0%
pharma conference association international research preclinical program

BioNTech to Present Multiple Program Updates Across Modalities at ESMO Congress 2023
Published: 2023-10-16 (Crawled : 08:00) - globenewswire.com
SNY | News | $47.125 1.78% 1.75% 2.1M

Health Technology

| -15.51% | O: -0.26% H: 0.0% C: 0.0%
BNTX | News | $88.01 1.38% 1.36% 390K

Health Technology

| -15.03% | O: -5.24% H: 1.85% C: -1.2%
congress program

Innate Pharma Provides Update on Lacutamab Clinical Program
Published: 2023-10-05 (Crawled : 08:00) - biospace.com/
SNY | News | $47.125 1.78% 1.75% 2.1M

Health Technology

| -14.1% | O: 0.19% H: 0.0% C: 0.0%
IPHA | $2.28 -6.56% -7.02% 9.5K

Health Technology

| -2.02% | O: -9.31% H: 7.14% C: 7.14%
pharma update program

ROME Therapeutics Closes Oversubscribed $72 Million Series B Extension to Support Advancement of Lead Program into Clinical Development for Autoimmune Disease
Published: 2023-09-12 (Crawled : 12:00) - biospace.com/
JNJ | News | $149.12 0.82% 0.0% 9.3M

Health Technology

| -7.41% | O: 0.62% H: 0.0% C: 0.0%
SNY | News | $47.125 1.78% 1.75% 2.1M

Health Technology

| -14.86% | O: 0.77% H: 0.0% C: 0.0%
disease series extension program therapeutics

Neurophet, the first company in Korea, selected by Roche Diagnostics for Startup Creasphere's APAC innovation program
Published: 2023-09-05 (Crawled : 13:00) - prnewswire.com
SNY | News | $47.125 1.78% 1.75% 2.1M

Health Technology

| -13.78% | O: -0.93% H: 0.0% C: 0.0%
innovation program roche diagnostics

Launch of Insilico’s Phase II Program Highlights Generative AI Momentum
Published: 2023-08-14 (Crawled : 05:00) - biospace.com/
SNY | News | $47.125 1.78% 1.75% 2.1M

Health Technology